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We have developed a yeast-based model recapitulating neurotoxicity of α-synuclein fibrilization. This model recognized metal ions, known
risk factors of α-synucleinopathy, as stimulators of α-synuclein aggregation and cytotoxicity. Elimination of Yca1 caspase activity augmented
both cytotoxicity and inclusion body formation, suggesting the involvement of apoptotic pathway components in toxic α-synuclein
amyloidogenesis. Deletion of hydrophobic amino acids at positions 66–74 in α-synuclein reduced its cytotoxicity but, remarkably, did not lower
the levels of insoluble α-synuclein, indicating that noxious α-synuclein species are different from insoluble aggregates. A compound screen aimed
at finding molecules with therapeutic potential identified flavonoids with strong activity to restrain α-synuclein toxicity. Subsequent structure–
activity analysis elucidated that these acted by virtue of anti-oxidant and metal-chelating activities. In conclusion, this yeast-cell model as
presented allows not only fundamental studies related to mechanisms of α-synuclein-instigated cellular degeneration, but is also a valid high-
throughput identification tool for novel neuroprotective agents.
© 2005 Elsevier B.V. All rights reserved.Keywords: α-synuclein; Parkinson's disease; Phenotype-based model; Protein-aggregation; Yeast1. Introduction
Noxious α-synuclein amyloidogenesis is a common denom-
inator in a plethora of age-related brain disorders exemplified
most prominently by Alzheimer's, Diffuse Lewy Body and
Parkinson's disease [1]. In these examples, insoluble aggregates
of α-synuclein are found in extracellular plaques (as the non-
amyloid component), in Lewy bodies and as inclusions in
dopaminergic neurons, respectively. Extensive research has
recognized the propensity of α-synuclein to self-polymerize as aAbbreviations:MPTP, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SAR,
structure–analysis relationship; SYN, α-synuclein
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doi:10.1016/j.bbadis.2005.11.009prominent risk factor in the pathogenesis. Compelling evidence
supporting this mechanism comes from identification of
dominant mutations in the α-synuclein coding region that
promote aggregation and early disease onset [2,3]. Although the
mechanisms of α-synuclein amyloidogenesis and its related
cytotoxicity remain elusive, it appears that oxidative stress
triggers oligomerization, a first step towards formation of
insoluble aggregates [4]. Consistent with this view, redox-active
metal ions (such as iron) are considered as major risk factors by
virtue of their ability to produce reactive oxygen species (ROS)
in a cellular environment [5–7]. Since α-synuclein aggregation
may also promote ROS directly [8], its unrestrained amyloido-
genesis supposedly leads to a vicious cycle of ROS production
and aggregation. Thus, from different perspectives oxidative
stress plays a prominent role in disease onset and development
and therefore agents that either prevent the production of ROS
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of particular therapeutic interest.
Despite numerous studies the precise molecular events
leading to cellular degeneration and the role of α-synuclein
fibrilization is puzzling, perhaps most dramatically illustrated
by the fact as to no consensus exists whether soluble
protofibril species or matured aggregates incite neurotoxicity.
In fact, it has been postulated that supramolecular protein
aggregates are inert or even neuroprotective reservoirs of
otherwise harmful soluble species [9]. Studies using yeast-
based models [10,11] linked the formation of aggregates
directly to toxicity. In yeast cells α-synuclein appear to
possess membrane-binding activity [12] corroborating its
presumed physiological role in synaptic vesicle binding and
their recycling [13] and a genome-wide, unbiased screening
effort identified genes involved in lipid metabolism and
vesicle-mediated transport that that appear to increase α-
synuclein toxicity [14]. Collectively, these studies suggest that
aggregation-prone α-synuclein misconfomers may possess
noxious membrane-binding properties affecting cellular integ-
rity. Moreover, it qualified yeast as an excellent model
organism to study physiological and pathological features of
α-synuclein as they are found in normal and diseased brains.
In this study, we developed a yeast-based system to
investigate known (or suspected) environmental and genetic
cues that involve α-synuclein-provoked degeneration of
neuronal cells. Subsequently, this model was optimized and
used in high-throughput screens of chemical libraries to
search for molecules that alleviate α-synuclein-induced
cytotoxicity.
2. Materials and methods
2.1. Yeast strains, growth conditions and compound screening
Yeast media were prepared as described in [15]. Cells were grown in YPAD
medium or in synthetic complete (SC) medium lacking essential nutrients for
plasmid selection. Yeast strains used in this study were: BY4741, BY4743 [16];
rM101 (BY4741 yca1::KanMX), rM102 (BY4743 yca1::KanMX/yca1::KanMX);
W303a/α [17]; AD1–8 [18]. This strain bears 8 deletions of so-called MDR1
genes encoding for ABC transporters with xenobiotics efflux capacity.
Therefore use of this strain facilitates uptake of compounds [18]. rM103
(AD1–8 yca1::KanMX). For metal toxicity studies ZnSO4 (Merck) and FeCl3
(Sigma-Aldrich) were added to the medium. Growth assays on solid medium:
yeast cells were grown overnight at 30 °C in selective media until they reached
late log phase. Cell density was determined using a spectrophotometer and cells
were diluted to an OD600 of 1. Ten-fold serial dilutions were spotted and
incubated at 30 °C. Growth assays on liquid medium: cells were inoculated in 96
well microtiter plates (150 μl/well) at OD600 of 0,05 and incubated in time as
indicated in the figures. Growth was followed by measuring the turbidity at 600
nm using a standard microtiter plate reader (Multiskan Ascent; Thermo
Labsystems). The OD600 measurement for growth curves is the average of
triplicate measurements from several independent transformants.
For high-throughput screening a collection of 10,022 diverse compounds
were tested. To this end, strain rM102 was inoculated at OD600 of 0,0125 in SC-
URA containing 2 mM FeCl3 and subsequently dispensed in 96 well microtiter
plates. Compounds were dissolved in DMSO and added to the yeast culture at a
final concentration of 10 μg/ml. Growth was followed by measuring OD600
using a microtiter plate reader until control cultures (to which equal amounts of
DMSO without compound were added) reached an OD600 of approximately
0.15. The compounds were purchased from ComGenex (Hungary) and Sigma-
Aldrich.2.2. α-synuclein expression plasmids
cDNA's encoding human α-synuclein (wild type, A53T, A30P and Δ66–
77) were constitutively expressed in yeast cells using the triose phosphate
isomerase (TPI1) promoter and alcohol dehydrogenase (ADH1) terminator. To
this end, a DNA fragment containing the ADH1 terminator was cloned in the
XhoI site of pYX212 [11] resulting in plasmid pJW212T. Subsequently, PCR
fragments were generated encoding human α-synuclein and the mutant derivates
with primers: α-SYN1-F 5′-GAT CAG AAT TCC CAT GGA TGT ATT CAT
GAA AGG ACT TTC-3′ and α-SYN2-R 5′-GAT CAA GAT CTCT CGA GTT
AGG CTT CAG GTT CGT AGT CTT G-3′ using plasmids containing the
relevant cDNA's as template. These PCR fragments were subsequently cloned
(NcoI/XhoI) in vector pJW212T resulting in plasmids 212T-SYN(WT), 212T-
SYN(A53T), 212T-SYN(A30P) and 212T-SYN(Δ66–77). These α-synuclein
expression plasmids were transformed to appropriate yeast strains. Construction
of a plasmid 23SYN-GFP encoding α-synuclein-GFP fusion is described in
[11]. Cells were viewed using a Nikon Opitshot fluorescence microscope.
2.3. Western analysis
Yeast cell cultures were grown till an OD600 of 2–3. Cells were harvested
by centrifugation, washed in sterile water and the pellets were resuspended in
extraction buffer containing 10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.05%
Tween 20, 10% Glycerol, 5 mM EDTA, 1 mM DTT and a mixture of protease
inhibitors (Complete, Roche Molecular Biochemicals, Germany) and disrupted
by vortexing for 5 min in the presence of glass beads. To remove cell debris the
resulting suspension was spun down at 200×g and subsequently the supernatant
was centrifuged at 16,000×g. The resulting supernatant (soluble fraction) and
pellet (insoluble fraction) were separately taken up in loading buffer,
fractionated by 15% SDS-PAGE and blotted onto PVDF membrane.
Immunodetection was carried out using mouse anti-α-synuclein monoclonal
antibody (Zymed Laboratories Inc.) and donkey anti-mouse IgG polyclonal
antibody conjugated with alkaline phosphatase (Rockland, USA). Proteins were
visualized using NBT/BCIP ready-to-use tablets (Roche) according to the
manufacturer's instructions.3. Results and discussion
3.1. Expression of α-synuclein cDNA in yeast cells
To construct a cellular model of α-synucleinopathy, we
successfully developed several yeast strains expressing wild
type α-synuclein or two corresponding clinical mutants (A30P
and A53T) (Fig. 1a). When expressed as a GFP fusion, the
resulting chimeric protein concentrated at the plasma membrane
(Fig. 1b) indicating that it retained functionality with respect to
its reported lipid bilayer association [10,19]. Although
expression of α-synuclein in yeast cells did not result in an
obvious growth or viability phenotype on solid medium (Fig. 1c
left panel), detailed kinetic analyses of growth in liquid medium
revealed a moderate growth-inhibitory effect (Fig. 1e, solid
symbols).
3.2. Identification of extracellular and genetic cues that
provoke α-synuclein-instigated cytotoxicity
We studied the effect of metal ions on cytotoxicity since
these are considered major risk factors in developing toxic α-
synuclein aggregation [5]. Addition of Zn2+ or Fe3+ ions to
the growth medium led to a further α-synuclein-dependent
growth inhibition (Figs. 1c, d, e, 2a) indicating that, similar to
the situation in diseased brains, also in yeast metal ions
Fig. 1. Metal ions induce α-synuclein toxicity in yeast cells. (a) Western analysis of yeast cells expressing cDNA of human α-synuclein or mutants. Notations 212T(V),
SYN(WT), SYN(A53T) and SYN(A30P) refer to extracts fromW303a/α yeast strain transformed with empty control vector pJW212T, or with 212T-SYN-WT, 212T-
SYN-A53T, 212T-SYN-A30P, respectively. (b) Fluorescence microscopy of rM101 cells transformed with pUG23 (no insert) and 23SYN-GFP encoding GFP and α-
synuclein-GFP, respectively. (c, d, e) Growth characteristics of yeast cells expressing human wild-type α-synuclein or mutants on solid c, or liquid d,media containing
ZnSO4 and FeCl3. In panels c and d, the same strains were used as described in panel a. In panel d, black and open bars indicate growth in the presence of 16 mM
ZnSO4 and 2 mM FeCl3, respectively. Growth is normalized to vector-containing cells. Bars indicate standard deviation. In panel e, kinetics of growth is determined of
AD1–8 cells transformed with pJW212T (■, □) or 212T-SYN(WT) (●, ○) in the absence (solid symbols) or presence (open symbols) of FeCl3.
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synuclein mutants (A53T; A30P) also led to metal-dependent
toxicity but the extent of growth inhibition was more variable
(Fig. 1c).
Although it has been suggested that α-synuclein aggre-
gation may stimulate apoptosis, it remains elusive whether
programmed cell death itself is directly responsible for
neuronal loss, especially considering the observations that α-
synuclein may also exert an anti-apoptotic activity [20,21].
This prompted us to study whether Yca1, a caspase
involved in yeast apoptosis [22], modulated α-synuclein-
triggered toxicity. Deletion of YCA1, however, did notameliorate cytotoxicity compared to its isogenic wild type
strain but – contrary to an anticipated suppression of α-
synuclein toxicity – rather displayed an even further
reduction of growth (Fig. 2a, b). Interestingly, Yca1 has not
been recognized before as a modulator of α-synuclein toxicity
in a genome-wide screening approach [14], possibly due to
the fact that significant toxicity (at least in this experimental
set-up) is only observed in the presence of FeCl3. Since yca1
cells are unable to execute apoptosis, the observations suggest
that the caspase plays another, yet unprecedented role
independent of apoptosis, in preserving integrity of cells
coping with α-synuclein toxicity.
Fig. 2. Characterization of α-synuclein cytotoxicity in yeast cells. (a) Growth of wild type strain BY4743 and rM102 (yca1/yca1) transformed with pJW212T (no
insert) and 212T-SYN-WT in presence or absence of FeCl3 and (b) in liquid media containing 2 mM FeCl3. (■ BY4743 [pJW212T];□ rM102 [pJW212T];● BY4743
[212T-SYN-WT]; ○ rM102 [212T-SYN-WT]). (c) Aggregation of α-synuclein-GFP in strain rM101. Several cells are shown to indicate heterogeneity among cells
concerning inclusion formation. (d) Quantification of α-synuclein-GFP aggregation in strain BY4741 (wild type, open bars) and rM101 (yca1 mutant, black bars)
transformed with 23SYN-GFP. The percentage of cells with inclusions is determined as a function of FeCl3 and Yca1. Kinetics of growth (e) and Western analysis of
soluble and insoluble fractions (f) of strain rM103 transformed with pJW212T (□), 212T-SYN-WT (○) and 212T-SYN(Δ66–77) (●) in liquid media containing 2 mM
FeCl3.
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α-synuclein aggregation in vivo
To gain further insight in the involvement of Yca1 in α-
synuclein toxicity, we analyzed whether α-synuclein inclusions
are formed in yeast cells and whether iron ions and Yca1
caspase are modulators. Wild type and yca1 mutant cells
expressing a GFP-α-synuclein fusion protein were generated
and grown in the presence of iron ions. By fluorescence
microscopy of actively dividing cells, we observed heterolo-
gous populations with some containing GFP-α-synuclein
aggregates while most displayed plasma membrane-associated,
diffuse fluorescence (Fig. 2c). Quantification of the percentageof cells with aggregates (Fig. 2d) revealed that Fe3+ ions
increased the percentage of inclusion-containing cells, substan-
tiating the hypothesis that ferrous ions promote aggregation.
Moreover, yca1 mutant strains, for which expression of α-
synuclein is profoundly cytotoxic, also displayed high levels of
α-synuclein aggregates, even in the absence of iron ions. Thus,
Yca1 caspase activity did not only protect against α-synuclein-
elicited toxicity (Fig. 2a, b) but appears to play a more specific
role in counteracting or inhibiting aggregation. Collectively, the
data revealing ferrous ions and Yca1 as modulators of α-
synuclein cytotoxicity (Fig. 2a, b) and the fluorescence studies
(Fig. 2c, d) suggest a positive correlation of growth inhibition
and inclusion formation. We also note an unanticipated role of
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in detailing the involvement of caspases in neuronal α-
synuclein pathology. Since Yca1 is thought to be responsive
to oxidative stress [23], we hypothesize that α-synuclein
aggregation and/or FeCl3 may mediate increases in ROS
production for activating Yca1 which in turn may trigger an
as yet fully speculative activity involved in breakdown of
aggregation-prone α-synuclein misconfomers. Indeed, many
neurodegeneration-associated gene products (such as α-synu-
clein) have been recognized as substrates of caspases [24], a
significant finding considering the high substrate specificity of
caspases [25].
3.4. A stretch of hydrophobic amino acids (66–74) confers
cytotoxicity of α-synuclein
Since cellular degeneration appears to be intimately linked
with formation of inclusion bodies (Fig. 2d), we went on to
study whether a previously identified stretch of hydrophobic
amino acids (66–74) required for in vitro self-association [26]
mediates cytotoxicity. The contribution of these amino acids
regarding in vivo cytotoxicity was defined by expressing a
mutant version of α-synuclein with residues 66–74 deleted
(αSYNΔ66–74) in yca1 cells. Expression of αSYNΔ66–74 caused
almost no growth inhibition compared to wild type α-synuclein
(Fig. 2e) suggesting that this hydrophobic motif is required for
cytotoxicity (also using wild type yeast cells identical results
were obtained; data not shown). To establish whether this motif
affects α-synuclein solubility, we performed Western analysis
of yca1 cells expressing wild type α-synuclein or αSYNΔ66–74
in response to FeCl3 (Fig. 2f). We observed that the levels of
insoluble αSYNΔ66–74 are equal (if not higher) compared to
wild type α-synuclein irrespective of the presence of extracel-
lular FeCl3 (note that addition of FeCl3 as such leads to a
decrease in cellular α-synuclein). These data demonstrate that,
although residues 66–74 mediate toxicity, it does not lower the
levels of α-synuclein in the insoluble fraction indicating that
precipitation alone is not sufficient to elicit toxicity. These
findings may seem surprising considering the results (see
above) uncovering a correlation of (full length!) α-synuclein
toxicity and in vivo inclusion formation. Apparently, formation
of insoluble aggregates is not toxic per se (in fact, it has even
been suggested that soluble protofibrils rather than insoluble
aggregates of α-synuclein confer cytotoxicity [27]) suggesting
that noxious α-synuclein amyloidogenesis requires specific
conformational or biophysical characteristics which require
residues 66–74. Thus, aggregates or protofibrils of wild type α-
synuclein may affect cellular integrity negatively, while
precipitation of αSYNΔ66–74 may not be harmful.
3.5. High-throughput screening of a small molecule library
identified flavonoids counteracting α-synuclein cytotoxicity
To further characterize the mechanisms involved in α-
synuclein pathogenesis, we tested about 10,000 compounds to
identify molecules that counteracted cytotoxicity. The effect of
the compounds on growth was evaluated using FeCl3-challenged yca1 cells (rM103) expressing wild-type α-synu-
clein since this was experimentally the most robust and
reproducible assay (Fig. 2b). To facilitate uptake of compounds
into the yeast cell, a genetic background was used with multiple
genomic deletions of (MDR1) genes encoding xenobiotics
efflux pumps. Since addition of 2 mM FeCl3 to the medium is
inherently toxic, compounds that either reduce the toxic
properties of FeCl3 or α-synuclein or both will be identified
as growth enhancers. We would like to point out that
suppression of inherent FeCl3 toxicity may be of therapeutic
interest since ferrous ions are considered as an important risk
factor of triggering neuronal degeneration in diseased brains (at
least in part by stimulating α-synuclein aggregation). Two
compounds were identified, i.e., quercetin and (−)-epigalloca-
techin-3-gallate, that were found to increase growth of α-
synuclein cells (Fig. 3) indicating a inhibitory activity of α-
synuclein cytotoxicity. This effect was found, at least partly,
independent of FeCl3 since also in the absence of FeCl3 growth
of α-synuclein cells was improved.
However, also FeCl3-grown parental cells (open bars)
displayed a modest growth improvement, although far less
than of α-synuclein cells, indicating that the compounds were
able – to some extent – to mitigate FeCl3 toxicity.
Both compounds acted with EC50 values in the low
micromolar range (Fig. 3b), indicating considerable potency
towards relieving cytotoxicity. Quercetin and (−)-epigalloca-
techin-3-gallate belong to the large group of flavonoids that are
commonly found in fruit, vegetables and green tea and they are
thought to possess a broad range of pharmacological activities
due to their strong anti-oxidant and metal chelation properties.
The anti-oxidant activities of the compounds could explain the
ability to inhibit α-synuclein-mediated cytotoxicity since its
aggregation is thought to promote harmful ROS production in
vivo [8]. The metal chelation (and anti-oxidant) properties are
likely to be responsible for countering inherent FeCl3 toxicity as
it is observed with parental cells challenged with ferrous ions
(see discussion above and Fig. 3a). Noteworthy in this context
are in vitro studies that recognized flavonoids as agents with
protein anti-fibrilization activity [28,29] although we could not
observe a reduction of α-synuclein in the insoluble fraction of
quercetin treated cells (data not shown). Nonetheless, (−)-
epigallocatechin-3-gallate has been shown neuroprotective in a
(MPTP-induced) animal model of dopaminergic degeneration
[30] demonstrating that the identified molecules are efficacious
in a relevant and well-validated model. Our data extent these
conclusions considerably by demonstrating that these flavo-
noids counteract the cytotoxic properties of α-synuclein toxicity
directly in a cellular context.
Structure–analysis relationship (SAR) studies of flavonoids
[31,32] revealed metal chelation sites between 4-oxo and
adjacent hydroxyl groups (3 and 5 positions), while also ortho-
oriented hydroxyl-groups on the B ring appeared to have metal-
binding properties. The same structural configuration was found
essential for scavenging radicals, showing that metal chelation
and anti-oxidant activity are intimately linked. We performed
SAR studies of some quercetin analogues to test structural
properties with in vivo relevance for inhibition of α-synuclein
Fig. 3. Identification of polyphenols as protective agents against α-synuclein-instigated cellular degradation. (a) Growth-restoration of strain rM103 (yca1)
transformed with pJW212T (open bars) and 212T-SYN-WT (black bars) in medium without (left panel) or with (right panel) 2 mM FeCl3 with varying concentrations
of quercetin or (−)-epigallocatechin gallate. Growth is normalized to 0 mM compound. (b) Dose–response curves of strain rM103 transformed with 212T-SYN-WT.
Growth was determined as a function of the quercetin or (−)-epigallocatechin gallate concentration. (c) Structure–activity relationship analysis of several flavonoids.
EC50 values are indicated in parenthesis.
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are of particular importance since their removal reduced or
abolished activity (quercetin vs. keamferol and galagin,
respectively) (Fig. 3c). Also the hydroxyl group at the 3
position was found important (quercetin vs. luteolin) whereaschanging the hydroxyl content of the A ring did not have any
significant impact (fisetin). Clearly, the SAR study suggests that
metal chelation and/or radical scavenging are important
structural properties to counteract α-synuclein toxicity in
vivo. We conclude that oxidative stress plays a determining
318 G. Griffioen et al. / Biochimica et Biophysica Acta 1762 (2006) 312–318role in α-synuclein-instigated cellular degeneration and thus
qualifies anti-oxidants and/or metal chelators as legitimate
candidates for therapeutic intervention in α-synucleinopathies.
Collectively, the data reported here divulge a phenotype-
based yeast model that recapitulates pathological properties of
human α-synuclein. This cellular model allows further
fundamental studies with respect to the underlying mechanisms
of aggregation and cytotoxicity, and to define environmental
and genetic modulators in vivo of α-synuclein-mediated
cytotoxicity. The model will also allow and facilitate the search
for disease-modifying agents. The identification of flavonoids
as inhibitors of toxicity already dramatically illustrated the
capability of this model as a powerful tool for high-throughput
screening to identify, and subsequently optimize, novel
molecular entities with therapeutic potential.Acknowledgments
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